Table 3.
Detailed information of discordant cases for PD-L1 expression among paired samples
| No. | Specimen 1 | Time interval | Specimen 2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Type | VTC | Treatment | Staining intensity | PD-L1% | Type | VTC | Treatment | Staining intensity | PD-L1% | ||
| 1 | Surgical resection (lung) | 10,000 | NT | 3+ | 70 | 18.5 m | MPE | 10,000 | AITa | 3+ | 40 |
| 2 | Subaxillary mass biopsy | 790 | CM, AIT | 1+ | 15 | 10.2 m | MPE | 10,000 | CMa, AIT | 3+ | 90 |
| 3 | CTG-CN (lung) | 400 | NT | 1+ | 45 | 5.1 m | MPE | 100,000 | TGTa | 3+ | 90 |
| 4 | CTG-CN (lung) | 5000 | NT | 1+ | < 1 | 1.6 m | MPE | 10,000 | CMa, EBRTa | 3+ | > 90 |
| 5 | Surgical resection (LN) | 30,000 | NT | 1+ | 15 | 3 d | MPE | 56,000 | NT | 2+ | 70 |
| 6 | MPE | 320 | CM | 1+ | 20 | 0 d | Pleural biopsy | 240 | CM | 2+ | 70 |
| 7 | MPE | 5000 | NT | 2+ | 50 | 0 d | Surgical resection (LN) | 10,000 | NT | 2+ | 5 |
| 8 | MPE | 6000 | NT | 2+ | 55 | 0 d | Endobronchial FB | 450 | NT | 1+ | 15 |
| 9 | MPE | 150,000 | NT | 3+ | > 90 | 1 d | Endobronchial FB | 234,000 | NT | 1+ | 10 |
| 10 | MPE | 80,000 | NT | 3+ | > 90 | 2 d | CTG-CN (lung) | 37,100 | NT | 2+ | 20 |
| 11 | MPE | 500 | NT | 3+ | > 90 | 2 d | Endobronchial FB | 400 | NT | 1+ | 40 |
| 12 | MPE | 30,000 | NT | 3+ | > 90 | 4 d | Pleural biopsy | 1060 | NT | 2+ | 35 |
| 13 | MPE | 125 | NT | 2+ | 20 | 6 d | Pleural biopsy | 450 | NT | 1+ | < 1 |
| 14 | MPE | 10,000 | NT | 3+ | 90 | 10 d | Lymph node biopsy | 550 | NT | 1+ | 2 |
| 15 | MPE | 1540 | NT | 1+ | 20 | 19.1 m | Pleural biopsy | 4520 | TGTa | 1+ | < 1 |
Abbreviation: VTC viable tumor cells, MPE malignant pleural effusion from thoracentesis, PD-L1 programmed cell death ligand-1, CTG-CN computed tomography-guided core needle biopsy, FB forceps biopsy, NT no treatment, CM chemotherapy, TGT targeted therapy, AIT adoptive cellular immunotherapy, EBRT external beam radiotherapy; adifferent from previous treatments; Specimen 1 obtained earlier than specimen 2